JPS6168422A - Ｌｐｆ−ｈａの精製方法 - Google Patents
Ｌｐｆ−ｈａの精製方法Info
- Publication number
- JPS6168422A JPS6168422A JP59190244A JP19024484A JPS6168422A JP S6168422 A JPS6168422 A JP S6168422A JP 59190244 A JP59190244 A JP 59190244A JP 19024484 A JP19024484 A JP 19024484A JP S6168422 A JPS6168422 A JP S6168422A
- Authority
- JP
- Japan
- Prior art keywords
- lpf
- gel
- dextran sulfate
- dextran
- bordetella pertussis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000746 purification Methods 0.000 title description 5
- 239000000499 gel Substances 0.000 claims abstract description 25
- 229920002307 Dextran Polymers 0.000 claims abstract description 17
- 241000588832 Bordetella pertussis Species 0.000 claims abstract description 14
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 14
- 239000005017 polysaccharide Substances 0.000 claims abstract description 14
- 238000001179 sorption measurement Methods 0.000 claims abstract description 5
- 229920005654 Sephadex Polymers 0.000 claims abstract description 4
- 239000007853 buffer solution Substances 0.000 claims abstract description 4
- 238000010828 elution Methods 0.000 claims abstract description 4
- 239000011543 agarose gel Substances 0.000 claims abstract description 3
- 239000012535 impurity Substances 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims description 24
- 229960002086 dextran Drugs 0.000 claims description 13
- 150000004676 glycans Chemical class 0.000 claims description 10
- 239000000243 solution Substances 0.000 claims description 10
- 229960000633 dextran sulfate Drugs 0.000 claims description 7
- 238000005406 washing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 5
- 229940066827 pertussis vaccine Drugs 0.000 abstract description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000002158 endotoxin Substances 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 201000005702 Pertussis Diseases 0.000 description 5
- 230000001766 physiological effect Effects 0.000 description 5
- 101001078385 Homo sapiens Haptoglobin Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 102000050796 human HP Human genes 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000588779 Bordetella bronchiseptica Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000014702 Haptoglobin Human genes 0.000 description 1
- 108050005077 Haptoglobin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 101150114751 SEM1 gene Proteins 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000011000 absolute method Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- MQRJBSHKWOFOGF-UHFFFAOYSA-L disodium;carbonate;hydrate Chemical compound O.[Na+].[Na+].[O-]C([O-])=O MQRJBSHKWOFOGF-UHFFFAOYSA-L 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- -1 sulfate ester Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59190244A JPS6168422A (ja) | 1984-09-10 | 1984-09-10 | Ｌｐｆ−ｈａの精製方法 |
| KR1019850005097A KR890001003B1 (ko) | 1984-07-19 | 1985-07-16 | Lpf-ha의 정제방법 |
| AU45093/85A AU571713B2 (en) | 1984-07-19 | 1985-07-17 | Method of purification of lpf-ha from bordetella pertussis |
| EP85108983A EP0170162B1 (en) | 1984-07-19 | 1985-07-18 | Method for the purification of leukocytosis-promoting factor haemagglutinin |
| AT85108983T ATE52694T1 (de) | 1984-07-19 | 1985-07-18 | Verfahren zur reinigung vom leukocytosisf¯rderungsfaktor haemagglutinin. |
| DE8585108983T DE3577658D1 (de) | 1984-07-19 | 1985-07-18 | Verfahren zur reinigung vom leukocytosis-foerderungsfaktor haemagglutinin. |
| CA000487035A CA1239104A (en) | 1984-07-19 | 1985-07-18 | Method for the purification of lpf-ha |
| US07/122,576 US4885359A (en) | 1984-07-19 | 1987-11-16 | Method for the purification of LPF-HA |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59190244A JPS6168422A (ja) | 1984-09-10 | 1984-09-10 | Ｌｐｆ−ｈａの精製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6168422A true JPS6168422A (ja) | 1986-04-08 |
| JPS6241692B2 JPS6241692B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1987-09-04 |
Family
ID=16254905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59190244A Granted JPS6168422A (ja) | 1984-07-19 | 1984-09-10 | Ｌｐｆ−ｈａの精製方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6168422A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) |
-
1984
- 1984-09-10 JP JP59190244A patent/JPS6168422A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6241692B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1987-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Woodin | Fractionation of a leucocidin from Staphylococcus aureus | |
| Nagai et al. | Specific skin-reactive protein from culture filtrate of Mycobacterium bovis BCG | |
| US4704274A (en) | Method for the purification of LPF-HA | |
| US4138287A (en) | Purifying and isolating method for hepatitis virus to use in preparing vaccine | |
| Seegers et al. | Further studies on the purification of thrombin | |
| US3686395A (en) | Process for preparation of storage stable hepatitis-free serum | |
| JPH0231689A (ja) | 百日咳トキシンの精製法 | |
| US4563303A (en) | Method for purification of filamentous hemagglutinin | |
| JPH05506649A (ja) | 百日咳菌外膜蛋白質の精製方法 | |
| NO137427B (no) | Apparat til fremstilling av st¦pte byggeelementer | |
| EP0175841B1 (en) | Method for the production of pertussis component vaccine and combined vaccine of pertussis antigen; diphtheria toxoid and tetanus toxoid | |
| JPS62258326A (ja) | ボルデテラ属細菌の蛋白質抗原の精製方法 | |
| DE69025375T2 (de) | Verfahren | |
| JPS6168422A (ja) | Ｌｐｆ−ｈａの精製方法 | |
| US4885359A (en) | Method for the purification of LPF-HA | |
| JP2019163212A (ja) | スフェロイド形成促進剤の濃縮方法および精製方法。 | |
| Jönsson | Purification and some properties of a protease from Alternaria tenuissima | |
| JPS6241691B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| JPS60218326A (ja) | 線維状赤血球凝集素の精製方法 | |
| GB1601744A (en) | Processes for the purification of interferon certain new and useful intermediates formed therein the purified interferon thus produced and pharmaceutical compositions containing | |
| JPS641447B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE4133707A1 (de) | Verfahren zur reinigung von streptolysin o, intaktes streptolysin o erhaeltlich nach diesem verfahren und seine verwendung | |
| US3650903A (en) | Method of production of fibrinolytic material | |
| Miller et al. | Prothrombin activation by encephalitogenic brain protein | |
| JP3747077B2 (ja) | 百日咳菌由来感染防御成分の分離取得方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |